Nanotechnology Now

Heifer International

Wikipedia Affiliate Button


Home > Press > Combination of Introgenís Nanoparticles Demonstrate Increased Efficacy in the Treatment of Metastatic Lung Cancer

Two powerful tumor suppressor genes, p53 and FUS1, administered intravenously in nanoparticle formulations were capable of significantly shrinking metastatic tumors in models of human lung cancer, according to investigators at The University of Texas M. D. Anderson Cancer Center. Molecular cancer therapies using these genes, p53 and FUS1, are in clinical-stage development by Introgen Therapeutics (NASDAQ:INGN). The technologies are included in a broad portfolio of intellectual properties licensed exclusively to Introgen from M. D. Anderson Cancer Center and other institutions.

Combination of Introgenís Nanoparticles Demonstrate Increased Efficacy in the Treatment of Metastatic Lung Cancer

AUSTIN, Texas | Posted on January 16th, 2007

The study, published in the January 15 issue of the journal Cancer Research, found that each of the nanoparticle tumor suppressors was effective therapy but more powerful results were observed when the treatments were combined. Systemic therapy with combined p53 and FUS1 nanoparticles in disseminated, metastatic lung cancers decreased the number of human lung tumors by 75 percent and cut their size by 80 percent. The studies also showed that the nanoparticle treatments had no demonstrable adverse effects on normal cells.

Abnormalities of the p53 and FUS1 tumor suppressors are among the most common molecular defects found in human cancers. The mechanism of the increased activity of the combined therapy was determined. The restoration of FUS1 function prevented the breakdown of the administered p53 resulting in its increased ability to destroy tumor cells.

This novel treatment strategy − the first time that two functional tumor suppressor genes have been used in a nanoparticle treatment − may offer a promising clinical treatment for lung and other cancers, according to lead author Lin Ji, Ph.D., assistant professor in the Department of Thoracic & Cardiovascular Surgery research at M. D. Anderson.

Robert E. Sobol, M.D., Introgen's senior vice president, Medical and Scientific Affairs stated, "These results further support our continued clinical development of p53 and FUS1 tumor suppressor therapies. These nanoparticle formulations facilitate treatment of disseminated cancers and validate the important concept of combining tumor suppressors selected to work synergistically in killing cancer cells while leaving normal cells unharmed."

In this study, the researchers tested the combined FUS1/p53 nanoparticles against four different human lung cancers as well as in normal non-cancerous cells. The treatment dramatically inhibited tumor cell growth in all four lung cancers tested, they said. It also induced cell death in the tumors, likely through the activation of p53 and FUS1 mediated gene functions that resulted in the killing of cancer cells but not normal cells.


About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be ďforward-lookingĒ statements, including those relating to Introgenís future success with its clinical development program with p53 and FUS1 for treatment of cancer or other diseases. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgenís operations and business environment, including Introgenís stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgenís product candidates, the ability to obtain the appropriate regulatory approvals, Introgenís patent protection and market acceptance, as well as other risks detailed from time to time in Introgenís filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editorís Note: M. D. Anderson Cancer Center also issued a news release about this publication. It may be found at .

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgenís Website at: .

For more information, please click here

Introgen Therapeutics, Inc.
C. Channing Burke, 512-708-9310 Ext. 322

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Patent for the Novel Cancer Therapies Ė Ceramide Nanoliposomes March 4th, 2015

Arrowhead to Present at 2015 Barclays Global Healthcare Conference March 4th, 2015

Democratizing synthetic biology: New method makes research cheaper, faster, and more accessible March 3rd, 2015

Pens filled with high-tech inks for do-it-yourself sensors March 3rd, 2015


Enhanced Graphene Components for Next Generation Racing Yacht March 5th, 2015

American Chemical Society Presidential Symposia: nanoscience, international chemistry March 5th, 2015

Magnetic vortices in nanodisks reveal information: Researchers from Dresden and JŁlich use microwaves to read out information from smallest storage devices March 4th, 2015

CiQUS researchers obtain high-quality perovskites over large areas by a chemical method March 4th, 2015


The George Washington University Opens Science and Engineering Hall, Largest Building of Its Kind in D.C.: Building Represents Significant Investment in Research Programs and Facilities; Commitment to Solve Global Problems, Improve Lives of Millions March 5th, 2015

Anousheh Ansari Wins the National Space Society's Space Pioneer Award for "Service to the Space Community" March 5th, 2015

Enhanced Graphene Components for Next Generation Racing Yacht March 5th, 2015

Get ready for NanoDays! March 5th, 2015

Human Interest/Art

2015 Nanonics Image Contest January 29th, 2015

OCSiAl supports NanoART Imagery Contest January 23rd, 2015

EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015

Oxford Instruments Asylum Research Announces AFM Image Contest Winners January 11th, 2015

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project

© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE